Wednesday, 20 June 2018

BioLargo Spotlight Blog Post: Toxicity Studies


As our AOS water treatment system progresses toward commercialization, one of the standard questions I am often asked is whether there are potential adverse effects of AOS-treated water on aquatic organisms and the environment. As a word to the uninitiated, every water treatment technology must answer this question before it goes commercial. It might seem counter-intuitive that it’s necessary to prove that a water treatment technology doesn’t make toxic water, but it’s necessary to demonstrate to regulatory agencies that whatever magic goes on inside your treatment device doesn’t convert water contaminants into toxic compounds. In the the industry, these are commonly known as disinfection and decontamination by-products (DBPs), and it’s necessary for every technology to prove that their DBPs are either minimal or mitigated, and that they’re not toxic.




Thankfully, things look good for the AOS – all prior tests using cultured human cells suggest that AOS-treated water isn’t toxic. Next, we are working to prove that AOS-treated water isn’t toxic to aquatic life, which is both industry standard and necessary to progress to the commercial stage. To do this, a collaboration has been established with the University of Alberta’s Dr. Greg Goss. Dr. Goss is an expert on water quality assessment using aquatic models and has previously worked on similar projects with other companies. This project, funded by the National Engineering Research Council (NSERC) of Canada, will evaluate whether long-term exposure to AOS-treated water results in any adverse effect(s) on aquatic organisms. Either rainbow trout and/or water fleas will be exposed to AOS-treated municipal wastewater effluent and the effects on reproductive fecundity and/or gene expression will be compared to trout and water fleas exposed to the same wastewater, but untreated. Furthermore, using municipal wastewater effluent spiked with known environmental contaminants, it will be possible to demonstrate if the AOS actually provides protection from the effects of known contaminant on these organisms. 

Rainbow trout







 
Water flea

We’re confident that the results of this study will provide the necessary evidence of the environmental safety of our innovative AOS technology. This work provides one more piece of the puzzle required for safe implementation of the AOS to provide reliable and cost-efficient water treatment to multiple industries and applications. These results will also empower us in our progress toward taking the AOS to market, as they represent a necessary and important milestone for its commercialization.

Dr. Laura Patterson-Fortin
Lead Disinfection Research Scientist and Co-CSO

Monday, 11 June 2018

Continued Commercial Progress for BioLargo - Dennis Calvert Uptick Newswire Interview

BioLargo President and CEO Dennis Calvert appeared on Uptick Newswire's Stock Day podcast again today for an interview by Everett Jolly.

Listen to the full podcast below to hear about BioLargo's big success in the industrial odor control market with its superior product, CupriDyne® Clean. The company is marketing the product with great success to the solid waste management industry and now finding early success in the wastewater treatment industry. There are an estimated 16,000 public wastewater treatment facilities in the US, and Calvert comments, “There’s no reason every one of them couldn’t use our product – the trick is that they have to know about it.”


The company's other incubating products are steadily advancing toward commercialization, and once there they are both expected to create a huge splash. One is the Advanced Oxidation System (AOS), a novel and innovative water treatment technology designed to allow cost-efficient water treatment across a number of important industries and areas. The other is its Clyra Medical Technologies advanced wound care products that are in process now with the FDA for 510 (k) medical device classification, which is a huge and important step for those products. 

You can also go to Uptick Newswire to listen to the podcast here, and you can read their press release about the interview here!

Wednesday, 6 June 2018

Dennis Calvert Interview with Proactive Investors

BioLargo President and CEO Dennis Calvert was interviewed by Proactive Investors about our first big commercial success - CupriDyne Clean Industrial Odor and Volatile Organic Compound "VOC" Eliminator. The product has rapidly been attracting attention and generating contracts in the solid waste management and wastewater treatment industry.

See the full interview below, and read Proactive Investors' synopsis at their website here.

The company's most recent powerpoint presentation can also be seen at this link.

Tuesday, 5 June 2018

BioLargo's Presentation at 8th Annual LD Micro Invitational

BioLargo President and CEO Dennis Calvert presented yesterday at the 8th Annual LD Micro Invitational Conference in Bel Air, CA to an audience of investors. This presentation represents the company's most up-to-date corporate deck, so be sure to peruse it to learn more about our business!



BioLargo Spotlight: AOS and SAGD Water Grant


Hello again from Edmonton, this is BioLargo Water Senior Research Scientist Dr. Parastoo Pourrezaei. Today I want to bring you some information about what I believe is one of our most important development areas for the Advanced Oxidation System (AOS). As you may know, the AOS is a powerful water treatment technology with great potential to bring cost-efficient and reliable water treatment to diverse market applications, and this includes oil and gas water treatment and reuse. 

Within oil and gas water treatment, there exists a very important application: the treatment and reuse of water produced in steam assisted gravity drainage (SAGD) operations, a process commonly used to extract bitumen from oil sands. In this process, steam is injected underground to enable the extraction of bitumen from the formation, and as a consequence of this, a significant amount of contaminated water is produced, which we refer to as SAGD-produced water. Nowadays, there is a real push in the industry to treat that SAGD-produced water and reuse it in the process. By doing this, oil sands operations can avoid using an astronomical amount of fresh water that would normally be used in the process and avoid discharging an equally astronomical amount of highly contaminated water to the environment.

 













How can BioLargo’s AOS help address the SAGD problem? We have established in lab studies that the AOS is projected to be the most cost-efficient and energy-efficient option for treatment of Oil Sands Process-Affected Water (OSPW) (water produced by surface-mining in the oil sands), and that the AOS consistently eliminates 99% of naphthenic acids from OSPW. We believe that the AOS can similarly address SAGD water treatment and become the most energy- and cost-efficient solution for removal of soluble organics from SAGD water.

In April 2018, we at BioLargo started a new project, funded by the Natural Science and Engineering Research Council (NSERC) of Canada, and in collaboration with leading SAGD researcher at the University of Alberta Dr. Mohtada Sadrzadeh, to use a modified natural adsorbent before the AOS to create robust, cost-efficient solution for SAGD-produced water treatment and reuse. This project has the potential to allow the AOS to reduce both freshwater use through recycling as well as water contamination issues in Canada’s biggest and most influential industry, the oil sands industry.

What is a BioLargo Spotlight?
It’s an exciting time at BioLargo. We’re moving fast, and it can be difficult to keep our stockholders and the investing public informed of our progress. In light of this, we will be posting a series of short articles titled “BioLargo Spotlight”, highlighting certain business activities and other important information in between our required SEC filings. Of course, these do not replace our public filings, which contain more complete information than can be delivered in this forum, and thus we urge you to carefully read and rely on those filings for definitive information, and to review our risk factors and caution regarding forward-looking statements. We are optimistic about our business as we work hard to continue to grow and ultimately generate profits for our stockholders.   

Legal Disclaimer
Our attorneys remind us that while we believe these developments are important and that these small victories could add up and lead to big victories, at this stage they do not rise to the level of an official material disclosure. As the size and magnitude of these developments become material, we will naturally report that information in an 8-K and our regular SEC filings.

Wednesday, 30 May 2018

BioLargo Spotlight: Advanced Oxidation System (AOS) Versus Waterborne Viruses


Hello, my name is Dr. Laura Patterson-Fortin, lead for BioLargo Water’s disinfection R&D team in Edmonton. My team has previously reported many exciting results using the AOS for water disinfection. In today’s blot post, I hope to inform our shareholders and followers of some really positive recent results we’ve achieved in virus disinfection, and to share a little bit on how and why we choose to use viral surrogates for our studies, namely Bacteriophages T4 and MS2. 

First, the results! You may have read in previous disclosures that our AOS consistently eliminates about 4 logs (or 99.99%) of Bacteriophage MS2 from water, which is more than a sufficient level of virus disinfection for most target water treatment applications. We’re proud to say that because of physical improvements to our AOS, we’ve increased our MS2 disinfection performance rate to 6 logs (or 99.9999%), which is effectively a 100x increase in performance. This is terrific news, because once we prove this increase in virus disinfection performance translates at industrial scale, we believe it will represent a significant competitive advantage over other water treatment technologies due to the AOS' greater kill rates and lower operational costs compared to other water disinfection technologies in many applications.

Source: The Institute for Molecular Virology















Why do we (and others who do water disinfection development work) use Bacteriophage MS2 to test our AOS’ virus disinfection capabilities? A fine question, reader. The reason we test our technology’s ability to kill viruses using a surrogate like MS2 is that it’s a safe, cost-effective, and relevant way to assess virus disinfection performance compared to directly testing with highly dangerous human pathogens like hepatitis A, Norwalk virus, or Enteroviruses. Typically, only very special (and very expensive) labs with strict certifications work with human viruses, and even if that weren’t the case, it’s very time-consuming and expensive to work with human viruses. This is why the scientific community generally accepts virus disinfection results with Bacteriophage MS2 and other surrogates, with the understanding that once a technology goes commercial it will be tested and certified to work against actual human viruses.

This is why we are very excited about our recent results with MS2 disinfection – they show that our AOS is a powerful tool for disinfecting water containing viruses, and we’re anxious to see it commercialized and treating water around the world.

If you found this post interesting, or you would like to learn more about virus disinfection, don’t hesitate to engage us on social media at BioLargo Water’s Twitter account @BioLargoWater and BioLargo’s Twitter @BioLargo, or at our Facebook page.


What is a BioLargo Spotlight?
It’s an exciting time at BioLargo. We’re moving fast, and it can be difficult to keep our stockholders and the investing public informed of our progress. In light of this, we will be posting a series of short articles titled “BioLargo Spotlight”, highlighting certain business activities and other important information in between our required SEC filings. Of course, these do not replace our public filings, which contain more complete information than can be delivered in this forum, and thus we urge you to carefully read and rely on those filings for definitive information, and to review our risk factors and caution regarding forward-looking statements. We are optimistic about our business as we work hard to continue to grow and ultimately generate profits for our stockholders.   

Legal Disclaimer
Our attorneys remind us that while we believe these developments are important and that these small victories could add up and lead to big victories, at this stage they do not rise to the level of an official material disclosure. As the size and magnitude of these developments become material, we will naturally report that information in an 8-K and our regular SEC filings.
 


widget